Sabahattin Ocak

Sabahattin Ocak

Auto-generated profile, based on publicly available information

Sabahattin Ocak

Department of Infectious Disease and Clinical Microbiology, Mustafa Kemal University, Hatay, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Turkish Journal of Parasitology
Verified
Journal Article
Closed access
SŞSelma İlKay Şahin
Selma İlKay Şahin
MÇMehmet Çabalak
Mehmet Çabalak
TBTayibe Bal
Tayibe Bal
SOSabahattin Ocak
Sabahattin Ocak
YÖYusuf Önlen
Yusuf Önlen
GÇGülnaz Çulha
Gülnaz Çulha
Cases with imported malaria have increased complication and mortality rates because of delayed diagnosis and treatment in non-endemic countries. This study aimed to investigate the incidence and clinical features of imported malaria in our clinic during the past 10 years. This retrospective study included 75 cases diagnosed as having imported malaria in our clinic between January 2008 and December 2017. The epidemiological data, laboratory findings, treatment data and clinical course of the cases were obtained from system records. Patients were predominantly male (%98.6) with a median age of 51 (23-64) years. All cases were infected with Plasmodium falciparum, had a recent travel history to Sub-Saharan African countries and none had received chemoprophylaxis before travel. The incidence of imported malaria showed a declining trend after 2015. The most common findings were fever (100%), thrombocytopenia (84%) and anemia (72%). Although 8% of patients had presented with severe malaria, none of them died. Despite increasing incidence of imported malaria in our country in recent years, there is a decrease in this number in our region. Since Turkey is one of the countries with the highest prevalence of imported malaria in the world, patients with fever and thrombocytopenia should be questioned whether or not they had a history of travel to malaria-endemic area.

1 August 2020 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
MÇMehmet Çabalak
Mehmet Çabalak
TBTayibe Bal
Tayibe Bal
MDMehmet Demir
Mehmet Demir
SOSabahattin Ocak
Sabahattin Ocak
YÖYusuf Önlen
Yusuf Önlen

29 April 2020 in Harran Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
MÇMehmet Çabalak
Mehmet Çabalak
TBTayibe Bal
Tayibe Bal
SOSabahattin Ocak
Sabahattin Ocak
Tr en Amaç: İmmünsupresif ilaç kullananlarda, hepatit B reaktivasyon riskine yönelik tarama yapılması önerilmektedir. Bu çalışmada immünsüpresif tedavi öncesi, Enfeksiyon hastalıkları kliniğine yönlendirilen hastalarda hepatit B virüsü (HBV), hepatit C virüsü (HCV) ve hepatit A virüsü (HAV) sonuçları retrospektif olarak irdelenmesi amaçlandı. Materyal ve Metod: Çalışmamızda Ocak 2018 - Aralık 2018 tarihleri arasında immünsüpresif tedavi öncesi, Enfeksiyon hastalıkları kliniğine yönlendirilen 148 hastanın hepatit B yüzey antijeni (HBsAg), hepatit B yüzey antikoru (Anti-HBs), hepatit B core protein antikoru (Anti-HBc IgG), anti hepatit C virüs antikoru (Anti-HCV) ve anti hepatit A virüs antikoru (Anti-HAV) hasta dosyalarından ve hastane otomasyon sisteminden retrospektif olarak incelendi. Bulgular: HBsAg pozitiflik oranı %4.1, Anti-HBs pozitiflik oranı %31.8, İzole Anti-HBc IgG pozitiflik oranı %1.4 ve iki hastada ise Anti-HBs bakılmamıştı. Anti-HCV pozitifliği %1.4 tespit edildi. Hastaların %79.7 Anti-HAV bakılmamış, Anti-HAV pozitifliği %12.2 ve Anti-HAV negatifliği %8.1 olarak saptandı. Sonuç: İmmünsüpresif tedavi öncesi tarama yapılmasına rağmen bazı taramaların eksik yapıldığı tespit edildi. Bu nedenle bu hastaları takip eden hekimlere eğitim verilmesi ve özellikle HBV enfeksiyonu konusunda farkındalık oluşturulmasını önermekteyiz. Background: Screening aimed at hepatitis B reactivation risk is recommended in patients using immunosuppressive drugs. The aim of this study was to investigate the results of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis A virus (HAV) retrospectively in patients referred to the infectious diseases clinic before immunosuppressive treatment. Materials and Methods: In our study, 148 patients who were referred to our infectious disease clinic before immunosuppressive therapeutic usage between January 2018-December 2018. Patients files and hospital automation sysytem were analyzed for Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (Anti-HBs), hepatitis B core protein antibody (Anti -HBc IgG), anti-hepatitis C virus antibody (Anti-HCV) and anti-hepatitis A virus antibody (anti -HAV) retrospectively. Results: HbsAg positivity rate was 4.1%, Anti-HBs positivity rate was 31.8%, Isolated Anti-HBc IgG positivity rate was 1.4% and Anti-HBs was not detected in two patients. Anti-HCV positivity was detected as 1.4%. Anti-HAV was not examined in 79.7% of the patients, 12.2% was determined to have positive Anti-HAV and 8.1% negative Anti-HAV. Conclusions: Since some screenings are incomplete despite screening performed for the patients, we recommend that physicians who follow patients receiving immunosuppressive therapy should be trained and raise awareness of HBV infection.

1 June 2023 in Flora the Journal of Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
HYHasibullah Yaqoobi
Hasibullah Yaqoobi
MÇMehmet Çabalak
Mehmet Çabalak
YÖYusuf Önlen
Yusuf Önlen
TBTayibe Bal
Tayibe Bal
SOSabahattin Ocak
Sabahattin Ocak

15 April 2023 in Hepatitis Monthly
Verified
Journal Article
Open access
PDF file
MÇMehmet Çabalak
Mehmet Çabalak
TBTayibe Bal
Tayibe Bal
SOSabahattin Ocak
Sabahattin Ocak
IBİsA Ahmet Bal
İsA Ahmet Bal
YOYusuf Onlen
Yusuf Onlen
Background: Glecaprevir/pibrentasvir (G/P) is a pangenotypic direct-acting antiviral (DAA) drug with a high resistance barrier. It has been used in patients with chronic hepatitis C in Turkey since March 2019. This drug's efficacy and safety data in Turkey are very limited, and there are not enough studies on real-life data. Objectives: In this study, we aim to present real-life data, efficacy, and safety for our patients. Methods: In this retrospective, observational, single-center study, 116 patients who were started on G/P (100mg/40mg) oral therapy at the infectious diseases clinic between March 2019 and December 2021 due to HCV were included. Of the 116 patients included in the study, 92 were analyzed. Demographic data of the patients, previous treatment experience, drug use, viral load (HCV RNA levels at the 4th week of treatment and 12th week after treatment), and viral genotype data were obtained retrospectively from the automation system. Statistical analysis IBM SPSS version 21.0 statistical package program was used. Results: Seventy-one (77.2%) of the patients were male, and 21 (22.8%) were female, with a mean age of 47.4 (18 - 89). Genotype distribution of patients 8.7% (n = 8) type 1a, 31.5% (n = 29) type 1b, 26.1% (n = 24) type 2, 22.9% (n = 21) type 3, 10.9% (n = 10) were type 4, 8.7% (n = 8) of the patients were treatment-experienced. In our study, there were no patients with cirrhosis. SVR-12 could not be obtained from a patient infected with only genotype 1a. In addition, this patient was co-infected with Hepatitis B. No side effects were observed in any of the patients that required treatment discontinuation. The SVR-12 rate was 98.6% with patients per protocol analysis (PP), but the SVR-12 rate was 77.2% with intention to treat analysis (ITT). Conclusions: In conclusion, this study suggested that G/P therapy in Turkey is used in real life with very high efficacy and tolerability. In addition, a significant change was observed in the genotype distribution previously reported in Turkey in the patient group we treated.

15 December 2022 in Mustafa Kemal Üniversitesi Tıp Dergisi
Verified
Journal Article
Closed access
HYHasibullah Yaqoobi̇
Hasibullah Yaqoobi̇
TBTayibe Bal
Tayibe Bal
MÇMehmet Çabalak
Mehmet Çabalak
YÖYusuf Önlen
Yusuf Önlen
SOSabahattin Ocak
Sabahattin Ocak
Nötropenik enterokolit çoğunlukla akut lösemili hastalar gibi mukozal hasarı indükleme potansiyeli yüksek hastalığı olanları ve yoğun kemoterapötik rejimleri alan hastaları etkilemektedir. Burada kemoterapi devamında ateş, karın ağrısı, bulantı, kusma, karında şişkinlik, ishal, ağız içinde yara şikayetleri ile başvuran, batın BT’ de diffüz duodenum duvar kalınlaşması saptanan 34 yaşında akut lenfoblastik lösemi tanılı nötropenik enterokolit olgusu sunulmuştur. Olgumuzu sunmaya değer kılan duodenal bölge tutulumu ile seyreden nötropenik enterokolit olmasıdır.